CANCER AND LEUKEMIA GROUP B
癌症和白血病 B 组
基本信息
- 批准号:6375474
- 负责人:
- 金额:$ 25.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1979
- 资助国家:美国
- 起止时间:1979-04-01 至 2003-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS related neoplasm /cancer aging antineoplastics bone marrow transplantation breast neoplasms cancer prevention cancer registry /resource carmustine chemoprevention cis platinum compound clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study cyclophosphamide doxorubicin drug resistance finasteride fluorouracil gastrointestinal neoplasms health care cost /financing hormone therapy human genetic material tag human subject human therapy evaluation interleukin 2 leucovorin leukemia lymphoma melanoma neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer surgery neoplasm /cancer vaccine oncology nursing paclitaxel pathology prostate neoplasms psychology quality of life respiratory neoplasm tamoxifen tissue resource /registry weight loss
项目摘要
DESCRIPTION (adapted from the applicant's abstract): The Comprehensive
Cancer Center of Wake Forest University continues to be a major accrue to
Cancer and Leukemia Group B protocols. A modest decrease in accrual is
noted for 1996 which reflects economic constraints and the influence of
managed care. We have obtained an R13 CA-74441 demonstration grant to
evaluate and strengthen the recruitment and retention of minorities in
cancer clinical trials. Further, we are applying through CALGB for the
minority initiative program to obtain data management support for East
Carolina University. They have access to a large minority population in
eastern North Carolina. The anticipation that first-line protocols for
leukemia, lymphoma, and advanced breast cancer will soon be available should
also strengthen our accrual in this grant period. Our institutional and
CCOP accrual to protocol #9399 (chemotherapy prevention of prostate cancer
with finasteride) is an expression of our ability to accrue large number of
patients quickly to cancer control clinical trials. Dr. David Hurd, Chair
of the Transplant committee and Dr. Electra Paskett, Chair of the Cancer
Control committee provide strong scientific contributions to CALGB and
further strengthen our accrual to clinical trials. Dr. Jim Atkins, Chairman
of the Southeast Cancer Control Consortium (SCCC), is developing a strong
regional program with increasing emphasis on the accrual of minorities to
clinical trials. Our strong community outreach clinical trials program is
focused to develop community techniques which will improve accrual to
clinical trials. The development of multi-disciplinary affinity groups in
breast, GI, GU, leukemia, lung, neuro-oncology, and oral head/neck cancer
will also strengthen our institutional contributions to Cancer and Leukemia
Group B.
描述(改编自申请人的摘要):综合
维克森林大学癌症中心继续是一个主要的积累,
癌症和白血病B组方案。 应计费用略有减少,
1996年的情况,反映了经济制约因素和
管理式护理 我们已经获得了R13 CA-74441示范赠款,
评估和加强少数群体的征聘和留用,
癌症临床试验。 此外,我们正在通过CALGB申请
少数民族倡议计划,以获得数据管理支持,为东
卡罗莱纳大学。 他们有机会接触到大量的少数民族人口,
北卡罗来纳州东部。 对于一线治疗方案的预期
白血病,淋巴瘤和晚期乳腺癌将很快可用,
也加强了我们在这一赠款期间的应计费用。 我们的机构和
方案#9399(前列腺癌的化疗预防)的CCOP累积
与financede)是我们的能力,积累大量的表达,
患者迅速进入癌症控制临床试验。 大卫赫德博士,主席
移植委员会主席Electra Paskett博士,癌症委员会主席
控制委员会为CALGB提供强大的科学贡献,
进一步加强我们的临床试验收益。 Jim阿特金斯博士,主席
东南癌症控制联盟(SCCC)正在开发一种强大的
区域方案,日益强调少数民族的利益,
临床试验 我们强大的社区外展临床试验计划是
专注于开发社区技术,以提高
临床试验 发展多学科的亲和团体,
乳腺癌、GI癌、GU癌、白血病、肺癌、神经肿瘤和口腔头颈癌
还将加强我们对癌症和白血病的机构贡献
B组。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID D HURD其他文献
DAVID D HURD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID D HURD', 18)}}的其他基金
CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
临床试验:硒和维生素 E 预防癌症试验(选择)
- 批准号:
8167005 - 财政年份:2010
- 资助金额:
$ 25.98万 - 项目类别:
CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
临床试验:硒和维生素 E 预防癌症试验(选择)
- 批准号:
7951366 - 财政年份:2009
- 资助金额:
$ 25.98万 - 项目类别:
SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
硒和维生素 E 预防癌症试验(选择)
- 批准号:
7607668 - 财政年份:2007
- 资助金额:
$ 25.98万 - 项目类别:
DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES
使用移植前样本中的鱼检测 MDS
- 批准号:
6514402 - 财政年份:2001
- 资助金额:
$ 25.98万 - 项目类别:
DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES
使用移植前样本中的鱼检测 MDS
- 批准号:
6283617 - 财政年份:2001
- 资助金额:
$ 25.98万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
- 批准号:
23K20355 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
- 批准号:
23K24782 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)